OR WAIT null SECS
August 10, 2022
Sartorius’ £415 million (US$429 million) acquisition of Albumedix is intended to bolster its portfolio with recombinant albumin-based solutions.
Catalent will acquire Metrics Contract Services for $475 million to expand high-potent capabilities and oral development and manufacturing capacity.
FDA has approved Coherus’ Cimerli (ranibizumab-eqrn) as an interchangeable biosimilar for all five indications of Lucentis.
Sanofi and Innovent have entered into a strategic collaboration to accelerate development of oncology medicines and expand their presence in China.
August 09, 2022
Amgen’s acquisition of Chemocentryx includes the autoimmune disease drug Tavneos (avacopan).
The European Commission has approved AstraZeneca and Merck’s Lynparza (olaparib) as an adjuvant treatment for BRCA-mutated HER2-negative high-risk early breast cancer.
August 05, 2022
La Jolla’s acquisition of Carterra’s LSA Platform is designed to advance their immunological and infectious disease research.
August 03, 2022
Ipsen and Marengo Therapeutics will collaborate to advance two precision immuno-oncology candidates.
August 02, 2022
The new facility in Albany, Ore., will support biopharmaceutical development and lyophilization services.
Novasep-PharmaZell will increase API production capacity at its Mourenx site with €7.3M investment.